Therapeutic agent for non-alcoholic fatty liver disease

A tablet, benzoxazole technology, applied in the field of non-alcoholic fatty liver disease prevention and/or therapeutic agent, can solve the problems such as unestablished recommended treatment methods, achieve the effect of inhibiting fat deposition and reducing Kupffer cells

Pending Publication Date: 2022-08-05
KOWA CO LTD
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are few reports of high-level evidence such as improvement of symptoms of fatty liver liver disease, and no highly recommended treatment method has been established.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic agent for non-alcoholic fatty liver disease
  • Therapeutic agent for non-alcoholic fatty liver disease
  • Therapeutic agent for non-alcoholic fatty liver disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] The role of Example 1 in the LDL receptor knockout mouse model of NASH

[0065] The role in high-fat / high-cholesterol diet (Western diet)-loaded LDL receptor knockout mice (Non-Patent Document 4) known to have fatty liver and hepatitis development, which is characteristic of NASH, was investigated.

[0066] In addition, in this test, (R)-2-{3-{[N-(benzoxazol-2-yl)-N-3-(4 disclosed in Example 85 of Patent Document 1 above was used. -Methoxyphenoxy)propyl]aminomethyl}phenoxy}butyric acid (compound A).

[0067] 1) Using animals:

[0068] Male LDL receptor knockout mice (B6.129S7-Ldlr / J, Jackson Laboratories). NASH was developed by ad libitum intake of Teklad Custom Research Diet (Harlan Teklad Company, TD. 88137) as a high fat / high cholesterol diet (Western diet) during 13 weeks from about 8 weeks of age.

[0069] 2) Group composition:

[0070] Mice were loaded with a high-fat / high-cholesterol diet (Western diet), and blood collection and body weight measurements...

Embodiment 2

[0082] Example 2 KK-A in the use of methionine / choline deficient dietary loads y Role in a mouse model of NASH

[0083] Investigated KK-A of MCD diet known to cause the onset of fatty liver disease characteristic of NASH by loading experimental animals with a methionine / choline deficient diet (MCD diet) y Effects in mice (Nakano S. et al., Hepatol Res., 38(10), 1026-39, 2008). In addition, in this test, as in Example 1, (R)-2-{3-{[N-(benzoxazol-2-yl)-N-3 disclosed in Example 85 of Patent Document 1 above was used -(4-Methoxyphenoxy)propyl]aminomethyl}phenoxy}butyric acid (compound A).

[0084] 1) Using animals:

[0085] Use male KK-A in experiments y mouse (KK-A y / TaJcl, Japan クレア Co., Ltd.). Mice were made to develop NASH by ad libitum MCD diet for 16 weeks starting at about 12 weeks of age.

[0086] 2) Group composition:

[0087] The groups were divided into the following groups: normal diet group, control group (MCD dietary load), compound A 0.25 mg...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a compound useful for preventing and treating non-alcoholic fatty liver disease. The present invention relates to a prophylactic and / or therapeutic agent for non-alcoholic fatty liver disease, which contains, as an active ingredient, (R)-2-{3-{[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy) propyl] aminomethyl} phenoxy} butyric acid, a salt thereof, or a solvate of the (R)-2-{3-{[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy) propyl] aminomethyl} phenoxy} butyric acid or the salt thereof.

Description

[0001] This application is a divisional application of a patent application with an application number of 201480033804.X on July 9, 2014 and the invention name is "therapeutic agent for non-alcoholic fatty liver disease". technical field [0002] The present invention relates to a preventive and / or therapeutic agent for nonalcoholic fatty liver disease. Background technique [0003] Metabolic syndrome (visceral fat syndrome) is attracting attention as a concept of so-called lifestyle diseases such as type II diabetes. Metabolic syndrome is defined as any two or more states of hyperglycemia, hypertension, and abnormal lipids in addition to visceral fat obesity. Metabolic syndrome promotes the development of arteriosclerosis and increases myocardial infarction and cerebral infarction. etc. risk of morbidity. [0004] Nonalcoholic fatty liver disease (NAFLD) is a fatty liver disorder not caused by alcohol consumption or a specific cause (virus, autoimmunity, etc.) In addition...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/423A61P1/16
CPCA61K31/423A61P1/16A61P43/00
Inventor 柴田治树滝沢俊明
Owner KOWA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap